Status:
COMPLETED
Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Advanz Pharma
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is designed to determine the safety of RSD1235 in patients with atrial fibrillation.
Eligibility Criteria
Inclusion
- Subject must have symptomatic AF
- Subject must have adequate anticoagulant therapy
Exclusion
- Subject may not have Class IV congestive heart failure.
- Subject may not have uncorrected electrolyte imbalance.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
254 Patients enrolled
Trial Details
Trial ID
NCT00281554
Start Date
October 1 2005
End Date
January 1 2007
Last Update
April 3 2008
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntsville, Alabama, United States, 35801
2
Atlanta, Georgia, United States, 30322
3
Chicago, Illinois, United States, 60637
4
Oak Lawn, Illinois, United States, 60453